June 27 (Reuters) - Mayne Pharma Group Ltd MYX.AX :
* MYX announces acquisition of US generic product portfolio MYX.AX
* Deal for US$652M
* Acquisition price represents less than 6 times projected FY 2017 EBITDA
* Acquired portfolio is expected to contribute sales of US$237M in FY 2017 with
gross margins greater than 50%
* Expected to be very significantly accretive to reported and cash earnings per
share in FY 2017
* Will fund the acquisition via an extension of its existing debt facility
* Says entered into an agreement to acquire 37 approved and 5 FDA filed
products from Teva Pharmaceutical Industries (NYSE:TEVA) Limited
* Will fund acquisition via fully underwritten A$601M 1-for-1.725 accelerated
non-renounceable entitlement offer and A$287M placement
* Entered into a binding agreement to acquire a portfolio of US generic
products from Teva and Allergan (NYSE:AGN_pa)
* Shares offered under entitlement offer will be issued at a price of A$1.28
per new share, representing a 9.2% discount
Source text for Eikon ID:nASX4yC1xk
For more news, please click here MYX.AX
Bengaluru Newsroom; +91 80 6749 1130